Phase I study of camrelizumab in patients with advanced solid tumors. 2023

Yuxiang Ma, and Jiaxin Cao, and Yang Zhang, and Qianwen Liu, and Wenfeng Fang, and Yunpeng Yang, and Yuanyuan Zhao, and Qing Yang, and Hongyun Zhao, and Li Zhang
Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, People's Republic of China.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies

Related Publications

Yuxiang Ma, and Jiaxin Cao, and Yang Zhang, and Qianwen Liu, and Wenfeng Fang, and Yunpeng Yang, and Yuanyuan Zhao, and Qing Yang, and Hongyun Zhao, and Li Zhang
July 2014, Cancer science,
Yuxiang Ma, and Jiaxin Cao, and Yang Zhang, and Qianwen Liu, and Wenfeng Fang, and Yunpeng Yang, and Yuanyuan Zhao, and Qing Yang, and Hongyun Zhao, and Li Zhang
December 2005, American journal of clinical oncology,
Yuxiang Ma, and Jiaxin Cao, and Yang Zhang, and Qianwen Liu, and Wenfeng Fang, and Yunpeng Yang, and Yuanyuan Zhao, and Qing Yang, and Hongyun Zhao, and Li Zhang
February 2018, The oncologist,
Yuxiang Ma, and Jiaxin Cao, and Yang Zhang, and Qianwen Liu, and Wenfeng Fang, and Yunpeng Yang, and Yuanyuan Zhao, and Qing Yang, and Hongyun Zhao, and Li Zhang
June 2015, Cancer chemotherapy and pharmacology,
Yuxiang Ma, and Jiaxin Cao, and Yang Zhang, and Qianwen Liu, and Wenfeng Fang, and Yunpeng Yang, and Yuanyuan Zhao, and Qing Yang, and Hongyun Zhao, and Li Zhang
September 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Yuxiang Ma, and Jiaxin Cao, and Yang Zhang, and Qianwen Liu, and Wenfeng Fang, and Yunpeng Yang, and Yuanyuan Zhao, and Qing Yang, and Hongyun Zhao, and Li Zhang
May 2014, Cancer chemotherapy and pharmacology,
Yuxiang Ma, and Jiaxin Cao, and Yang Zhang, and Qianwen Liu, and Wenfeng Fang, and Yunpeng Yang, and Yuanyuan Zhao, and Qing Yang, and Hongyun Zhao, and Li Zhang
July 2016, Oncotarget,
Yuxiang Ma, and Jiaxin Cao, and Yang Zhang, and Qianwen Liu, and Wenfeng Fang, and Yunpeng Yang, and Yuanyuan Zhao, and Qing Yang, and Hongyun Zhao, and Li Zhang
May 2009, Cancer chemotherapy and pharmacology,
Yuxiang Ma, and Jiaxin Cao, and Yang Zhang, and Qianwen Liu, and Wenfeng Fang, and Yunpeng Yang, and Yuanyuan Zhao, and Qing Yang, and Hongyun Zhao, and Li Zhang
March 2002, Clinical cancer research : an official journal of the American Association for Cancer Research,
Yuxiang Ma, and Jiaxin Cao, and Yang Zhang, and Qianwen Liu, and Wenfeng Fang, and Yunpeng Yang, and Yuanyuan Zhao, and Qing Yang, and Hongyun Zhao, and Li Zhang
December 2006, Cancer,
Copied contents to your clipboard!